

Geoffrey C Buckle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1302873/publications.pdf>

Version: 2024-02-01

27
papers

39,575
citations

516710

16
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

65785
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment outcomes of esophageal cancer in Eastern Africa: protocol of a multi-center, prospective, observational, open cohort study. <i>BMC Cancer</i> , 2022, 22, 82.	2.6	3
2	Risk Factors Associated With Early-Onset Esophageal Cancer in Tanzania. <i>JCO Global Oncology</i> , 2022, 8, e2100256.	1.8	11
3	Expanding oesophageal cancer research and care in eastern Africa. <i>Nature Reviews Cancer</i> , 2022, 22, 253-254.	28.4	5
4	An international report on bacterial communities in esophageal squamous cell carcinoma. <i>International Journal of Cancer</i> , 2022, 151, 1947-1959.	5.1	7
5	Esophageal sponge sampling: A promising approach for early detection of esophageal cancer in Africa's high-incidence region. <i>International Journal of Cancer</i> , 2021, 148, 1546-1547.	5.1	0
6	Optimal management of esophageal cancer in Africa: A systemic review of treatment strategies. <i>International Journal of Cancer</i> , 2021, 148, 1115-1131.	5.1	7
7	A Case-Control Study to Evaluate Environmental and Lifestyle Risk Factors for Esophageal Cancer in Tanzania. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 305-316.	2.5	21
8	Improving Access to Self-Expanding Metal Stents for Patients With Esophageal Cancer in Eastern Africa: A Stepwise Implementation Strategy. <i>JCO Global Oncology</i> , 2021, 7, 118-126.	1.8	5
9	TU1074 A STEPWISE APPROACH TO IMPLEMENTATION OF ESOPHAGEAL STENTING FOR PALLIATION OF ESOPHAGEAL CANCER IN EAST AFRICA. <i>Gastrointestinal Endoscopy</i> , 2020, 91, AB533.	1.0	1
10	The global burden of disease study 2013: What does it mean for the NTDs?. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005424.	3.0	181
11	Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study. <i>International Journal of Cancer</i> , 2016, 139, 1231-1240.	5.1	42
12	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	13.7	1,612
13	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	13.7	4,934
14	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	13.7	5,298
15	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	13.7	571
16	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 743-800.	13.7	4,951
17	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	13.7	1,544
18	Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 385, 117-171.	13.7	5,847

#	ARTICLE	IF	CITATIONS
19	Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2014, , 91.	2.7	8
20	The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2865.	3.0	796
21	Factors influencing time to diagnosis and initiation of treatment of endemic Burkitt Lymphoma among children in Uganda and western Kenya: a cross-sectional survey. <i>Infectious Agents and Cancer</i> , 2013, 8, 36.	2.6	39
22	Long-term Follow-up of a Phase II Trial of Chemotherapy Plus Hormone Therapy for Biochemical Relapse After Definitive Local Therapy for Prostate Cancer. <i>Urology</i> , 2013, 81, 611-616.	1.0	9
23	Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 507-512.	1.6	168
24	Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, 1729-1735.	2.5	71
25	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2197-2223.	13.7	7,061
26	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2163-2196.	13.7	6,376
27	Assessment of liver disease (noninvasive methods). <i>Current Opinion in HIV and AIDS</i> , 2011, 6, 465-471.	3.8	7